Now in JAMA Cardiology: 👴 ≥80 yrs with AFib 💊 *No* dose-reduction criteria 🎲 Lower-dose (vs. full-dose) ATC with edoxaban 👉 In elderly pts with AF, an "off-label" lower-dose anticoagulant led to fewer major bleeds & no increase in ischemic events. TIMI Study Group Robert Giugliano

🎉 Celebrating Over 7 Years of CCCTN! 🎉 Over 700 cardiac ICU beds strong! Thank you to our incredible team and collaborators. Here’s to more years of advancing cardiovascular care! ❤️ #CCCTN #Cardiology #Anniversary #CardiacCare #CriticalCareCardiology

Led by Dr. Ryan Keane et al. Cleveland Clinic Duke Health - new #CCCTN analysis characterizes the landscape of Adult Congenital Heart Disease #ACHD 🫀 across contemporary CICUs Now in JACC Journals #JACCAdvances 👇 jacc.org/doi/10.1016/j.…

Wow, another win for patients with #HFpEF and obesity! This time with dual incretin tirzepatide in #P3 #SUMMIT trial Co-primary endpoint of worsening HF events reduced by 38% HR 0.62 95% CI 0.41 to 0.95; P=0.026 investor.lilly.com/news-releases/…

The pre-shock ↔️ classic cardiogenic #shock continuum 💡What are the implications of an isolated low CO or isolated hypotension without end-organ injury? 💡 What about normotensive CS? Now in JACC Journals #JACCJF from Critical Care Cardiology Trials Network TIMI Study Group jacc.org/doi/10.1016/j.…

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online. timi.org/40th-anniversa…

See Yumi Kang, MD, PhD give her LBCT presentation on cardiovascular efficacy of evolocumab in patients with obesity from FOURIER (TIMI 59), tomorrow at 11:00 in Bishkek Michelle O'Donoghue Robert Giugliano #ESCCongress

See Paul M Haller's presentation on HF risk assessment using biomarkers from 32,041 patients in COMBINE-AF, tomorrow at 13:15 in Science Box 2 Robert Giugliano #ESCCongress

How often have you seen pts w/ AF-related systemic embolism in clinical routine? or was stroke you’re main concern? Elegant analysis by Samer Alsaid and Robert Giugliano presented at #ESCCongress using data of the 4 pivotal #DOAC RCTs forming the COMBINE-AF individual pt database

Evolocumab appears to attenuate the excess risk of MACE in patients with obesity. Yumi Kang, MD, PhD Michelle O'Donoghue Robert Giugliano #ESCCongress

In the COMBINE-AF study, #biomarkers NTproBNP, hs-cTnT & GDF-15 improve #heartfailure risk assessment in #Afib! hs-cTnT is equally important as #NTproBNP for HF risk assessment bit.ly/3ySKhNR #ESCCongress #JACC Paul M Haller Robert Giugliano TIMI Study Group

In 32,000 AF pts from COMBINE-AF, cardiac #biomarkers sign.⤴️ #heartfailure risk prediction! hs-cTnT as important as NTproBNP pointing to a promising dual-marker strategy. Results simultaneously published in JACC Journals Paul M Haller Robert Giugliano #ESCCongress

Can biomarkers improve HF risk assessment in AF patients? Superb analysis by Paul M Haller simultaneously published in JACC, shows hs-cTnT is as important as NTproBNP, with significant but lesser contribution from GDF-15. #COMBINE-AF

No increase in peri-procedural bleeding when comparing long-acting factor XI inhibitor abelacimab vs. rivaroxaban. Dr. Patel shares results from AZALEA-TIMI-71 substudy. #ESCCongress

#ESCCongress #LBCT Among pts undergoing invasive procedures in #AZALEA-TIMI 71, low and comparable rates of peri-procedural 🩸🩸 in those randomized to long-acting #FXI inhibition with abelacimab vs. rivaroxaban. Sid M. Patel

A new analysis from the AZALEA study presented as an #ESCCongress late-breaker by Sid M. Patel w/ the TIMI Study Group found approx. 1% of pts taking abelacimab experienced a major or CRNM bleed while undergoing a procedure. 👉 bit.ly/3z0MiaO.

Periprocedural data with #FXI inhibitor abelacimab promising, but more work in high #bleeding risk/urgent surgeries needed North American Thrombosis Forum Anticoagulation Forum Thrombosis Canada CanVECTOR Network Thrombosis UK Thrombosis, Leiden World Thrombosis Day European Thrombosis & Haemostasis Alliance (ETHA) European Society of Cardiology

Extracranial systemic embolic events (SEE) in AF are less frequent than ischemic stroke but just as fatal. Our IPD analysis of 71,683 AF pts from the pivotal DOAC vs. warfarin RCTs showed that DOACs are superior to warfarin in preventing SEE #ESCCongress2024

Recognition of preshock or early CS states is important to facilitate early identification, to guide appropriate triage and to enable prompt interventions aimed at delaying or preventing the onset of overt CS. bit.ly/3zeRsQn #JACCHF Sid M. Patel TIMI Study Group

🔥🔥 ☠️ for phenotypes along preshock -> CS continuum 👉 jacc.org/doi/full/10.10… JACC Journals #JACCHF Critical Care Cardiology Trials Network 🎯 Hypoperfusion +/- hypotension -> ⬆️☠️ 🎯 normotensive CS -> distinct CS phenotype 🎯 Identify pre-& early shock to improve #CardiogenicShock outcomes